The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1

Toxicology and Applied Pharmacology

Volumn 235, Issue 1, 2009, Pages 124-134

  Plant, Kathryn E ^a   Anderson, Elizabeth ^a   Simecek, Nicole ^b   Brown, Richard ^a   Forster, Sam ^a   Spinks, Jenny ^a   Toms, Nick ^c   Gibson, G Gordon ^a   Lyon, Jon ^b   Plant, Nick ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Apoptosis; Bipolar disorder; Lithium chloride; Microarray; Neuroprotection; Sodium valproate

Indexed keywords

CASPASE 3; LITHIUM CHLORIDE; SMALL INTERFERING RNA; STAUROSPORINE; TRANSCRIPTION FACTOR SIX1; VALPROIC ACID;

APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DNA MICROARRAY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; PROTEIN EXPRESSION; UPREGULATION;

ANTIMANIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE SILENCING; HOMEODOMAIN PROTEINS; HUMANS; LITHIUM CHLORIDE; NEUROBLASTOMA; STAUROSPORINE; UP-REGULATION; VALPROIC ACID;

EID: 59149096336     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.10.019     Document Type: Article

References (66)

1. Aghdam S.Y., and Barger S.W. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr. Alzheimer Res. 4 (2007) 21-31
2. Al-Assar O., and Crouch D.H. Inactivation of MAP kinase signalling in Myc transformed cells and rescue by LiCl inhibition of GSK3. Mol. Cancer 4 (2005) e13
3. Allen M.H., Hirschfeld R.M., Wozniak P.J., Baker J.D., and Bowden C.L. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am. J. Psychiatry 163 (2006) 272-275
4. Balfour J.A., and Bryson H.M. Valproic acid - a review of its pharmacology and therapeutic potential in indications other than epilepsy. Cns Drugs 2 (1994) 144-173
5. Behbakht K., Qamar L., Aldridge C.S., Coletta R.D., Davidson S.A., Thorburn A., and Ford H.L. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res. 67 (2007) 3036-3042
6. Bijur G.N., and Jope R.S. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J. Biol. Chem. 275 (2000) 7583-7590
7. Brancolini C., Benedetti M., and Schneider C. Microfilament reorganization during apoptosis: the role of Gas2, a possible substrate for ICE-like proteases. EMBO J. 14 (1995) 5179-5190
8. Brunello N. Mood stabilizers: protecting the mood.....protecting the brain. J. Affect. Disord. 79 (2004) S15-20
9. Bursch W., Oberhammer F., Jirtls R.L., Askari M., Sedivy R., Grasl-Kraupp B., Purchio A.F., and Schulte-Hermann R. Transfroming growth factor B1 as a signal for induction of cell death by apoptosis. Br. J. Cancer 67 (1993) 531-536
10. Chen G., Huang L.D., Jiang Y.M., and Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72 (1999) 1327-1330
11. Chen G., Zeng W.Z., Yuan L.D., Jiang Y.M., Zhao Z.H., and Manji H. The mood stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72 (1999) 879-882
12. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., Lu R.B., Gean P.W., Chuang D.M., and Hong J.S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 149 (2007) 203-212
13. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit. Rev. Neurobiol. 16 (2004) 83-90
14. Coletta R.D., Christensen K., Reichenberger K.J., Lamb J., Micomonaco D., Huang L., Wolf D.M., Muller-Tidow C., Golub T.R., Kawakami K., and Ford H.L. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6478-6483
15. De Sarno P., Li X.H., and Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43 (2002) 1158-1164
16. DelaCoste A., Fabre M., McDonell N., Porteu A., Gilgenkrantz H., Perret C., Kahn A., and Mignon A. Differential protective effects of Bcl-x(L) and Bcl-2 on apoptotic liver injury in transgenic mice. Am. J. Physiol.-Gastrointest. Liver Physiol. 40 (1999) G702-G708
17. Denkova R., Bourneva V., Staneva-Dobrovski L., Zvetkova E., Baleva K., Yaneva E., Nikolov B., Ivanov I., Simeonov K., Timeva T., and Yankov M. In vitro effects of inhibin on apoptosis and apoptosis related proteins in human ovarian granulosa cells. Endocr. Regul. 38 (2004) 51-55
18. Dennis Jr. G., Sherman D.T., Hosack D.A., Yang J., Gao W., Lane H.C., and Lempicki R.A. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4 (2003) R60
19. Di Daniel E., Mudge A.W., and Maycox P.R. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord. 7 (2005) 33-41
20. Ding D., and Greenberg M.L. Lithium and valproate decrease the membrane phosphatidylinositol/phosphatidylcholine ratio. Mol. Microbiol. 47 (2003) 373-381
21. Dunner D.L. Differential-diagnosis of bipolar disorder. J. Clin. Psychopharmacol. 12 (1992) S7-S12
22. Ford H.L., Kabingu E.N., Bump E.A., Mutter G.L., and Pardee A.B. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 12608-12613
23. Ford H.L., Landesman-Bollag E., Dacwag C.S., Stukenberg P.T., Pardee A.B., and Seldin D.C. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J. Biol. Chem. 275 (2000) 22245-22254
24. Fukunaga K., Ishigami T., and Kawano T. Transcriptional regulation of neuronal genes and its effect on neural functions: expression and function of forkhead transcription factors in neurons. J. Pharmacol. Sci. 98 (2005) 205-211
25. Gurvich N., and Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96 (2002) 45-66
26. Jann M.W., Bitar A.H., and Rao A. Lithium prophylaxis of tricyclic-antidepressant-induced mania in bipolar patients. Am. J. Psychiatry 139 (1982) 683-684
27. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
28. Kawakami K., Sato S., Ozaki H., and Ikeda K. Six family genes: structure and function as transcription factors and their role in development. Bioessays 22 (2000) 616-626
29. Kim A.J., Shi Y., Austin R.C., and Werstuck G.H. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. 118 (2005) 89-99
30. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., and Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321 (2007) 892-901
31. Kimelman D., and Xu W. beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 25 (2006) 7482-7491
32. Laclef C., Hamard G., Demignon J., Souil E., Houbron C., and Maire P. Altered myogenesis in Six1-deficient mice. Development 130 (2003) 2239-2252
33. Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., and Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 28 (2008) 2576-2588
34. Li C.M., Guo M., Borczuk A., Powell C.A., Wei M., Thaker H.M., Friedman R., and Klein U.T.B. Gene expression in Wilm's tumour mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am. J. Pathol. 160 (2002) 2181-2190
35. Li X., Bijur G.N., and Jope R.S. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4 (2002) 137-144
36. Li X., Oghi K.A., Zhang J., Krones A., Bush K.T., Glass C.K., Nigam S.K., Aggarwal A.K., Maas R., Rose D.W., and Rosenfeld M.G. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426 (2003) 247-254
37. Lu R., Song L., and Jope R.S. Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells. Neuroreport 10 (1999) 1123-1125
38. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., and Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20 (2001) 27-39
39. MacQueen G.M., Hajek T., and Alda M. The phenotypes of bipolar disorder: relevance for genetic investigations. Mol. Psychiatry 10 (2005) 811-826
40. Manji H.K., Moore G.J., and Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers. Br. J. Psychiatry 178 (2001) S107-119
41. McElroy S.L., Keck P.E., Pope H.G., and Hudson J.I. Valproate in the treatment of bipolar disorder - literature-review and clinical guidelines. J. Clin. Psychopharmacol. 12 (1992) S42-S52
42. Mendlewicz J., Souery D., and Rivelli S.K. Short-term and long-term treatment for bipolar patients: beyond the guidelines. J. Affect. Dis. 55 (1999) 79-85
43. Moroy T., Grzeschiczek A., Petzold S., and Hartmann K.U. Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/lpr mice. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10734-10738
44. Novak A., and Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell. Mol. Life Sci. 56 (1999) 523-537
45. Petropoulos H., and Skerjanc I.S. Beta-catenin is essential and sufficient for skeletal myogenesis in P19 cells. J. Biol. Chem. 277 (2002) 15393-15399
46. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
47. Phillips A., Bullock T., and Plant N. Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO. Toxicology 192 (2003) 219-227
48. Plant N.J., Horley N.J., Dickins M., Hasmall S.C., Elcombe C.R., and Bell D.R. The coordinate regulation of DNA synthesis and suppression of apoptosis is differentially regulated by the liver growth agents, phenobarbital and methylclofenapate. Carcinogenesis 19 (1998) 1521-1527
49. Pliskova M., Vondracek J., Vojtesek B., Kozubik A., and Machala M. Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both genotoxic and nongenotoxic events. Toxicol. Sci. 83 (2005) 246-256
50. Posmantur R., McGinnis K., Nadimpalli R., Gilbertsen R.B., and Wang K.K. Characterization of CPP32-like protease activity following apoptotic challenge in SH-SY5Y neuroblastoma cells. J Neurochem. 68 (1997) 2328-2337
51. Ray S.K. Currently evaluated calpain and caspase inhibitors for neuroprotection in experimental brain ischemia. Curr. Med. Chem. 13 (2006) 3425-3440
52. Reichenberger K.J., Coletta R.D., Schulte A.P., Varella-Garcia M., and Ford H.L. Gene Amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res. 65 (2005) 2668-2675
53. Roberts R., Soames A., Gill J., James N., and Wheeldon E. Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. Carcinogenesis 16 (1995) 1693
54. Serikaku M.A., and O'Tousa J.E. Sine oculis is a homeobox gene required for Drosophila visual system development. Genetics 138 (1994) 1137-1150
55. Silva R., Mesquita A.R., Bessa J., Sousa J.C., Sotiropoulos I., Leao P., Almeida O.F.X., and Sousa N. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3 beta. Neuroscience 152 (2008) 656-669
56. Spearing, M. 2001). Bipolar Disorder. NIH Publications 02-3679.
57. Sproule B. Lithium in bipolar disorder; can drug concentrations predict therapeutic effect?. Clin. Pharmacokinet. 41 (2002) 639-660
58. Strakowski S.M., DelBello M.P., and Adler C.M. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 15 (2001) 701-718
59. Thomas P. The many forms of bipolar disorder: a modern look at an old illness. J. Affect. Dis. 79 (2004) S3-8
60. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5116-5121
61. Wakabayashi K., Saito H., Ebinuma H., Saito Y., Takagi T., Nakamura M., Umezawa A., Hata J.S., and Ishii H. Bcl-2 related proteins are dramatically induced at the early stage of differentiation in human liver cancer cells by a histone deacetylase inhibitor projecting an anti-apoptotic role during this period. Oncol. Rep. 7 (2000) 285-288
62. Wlodarczyk B.C., Craig J.C., Bennett G.D., Calvin J.A., and Finnell R.H. Valproic acid-induced changes in gene expression during neurulation in a mouse model. Teratology 54 (1996) 284-297
63. Xu P.X., Zheng W., Huang L., Maire P., Laclef C., and Silvius D. Six1 is required for the early organogenesis of mammalian kidney. Development 130 (2003) 3085-3094
64. Yu Y., Khan J., Khanna C., Helman L., Meltzer P.S., and Merlino G. Expression profiling identifies the cytoskeletal organiser erzin and the developmental homeoprotein Six1 as key metastatic regulators. Nat. Med. 10 (2004) 175-181
65. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., and Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276 (2001) 31674-31683
66. Zheng W., Huang L., Wei Z.B., Silvius D., Tang B., and Xu P.X. The role of Six1 in mammalian auditory system development. Development 130 (2003) 3989-4000